TransMedics to benefit from new HHS organ oversight, says TD Cowen

TD Cowen says the Department of Health and Human Services is overhauling organ procurement and transplantation network and organ procurement organizations oversight, adding safety and transparency, and boosting donor sign-ups to cut organ waste and raise transplant volumes. TransMedics (TMDX) is best positioned to benefit from the new transplant logistics, the analyst tells investors in a research note. TD believes that as reforms expand the donor pool and reduce organ discards, TransMedics “could capture outsized growth.” The firm keeps a Buy rating on the shares with a $170 price target